Newsletter Tool

Editor’s Note: Vote now in #FierceMadness: The Best Biotech Name Tournament. The Final Four is open for voting!

Today’s Big News

Apr 5, 2024

Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff

Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public

Chutes & Ladders—Lonza lands new CEO after acquiring Roche site

Fierce Biotech Layoff Tracker 2024: Sanofi 'simplifies' R&D structure, team; Amylyx lays off 70% of staff

Featured

Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff

By Max Bayer

Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian to staff. The communication, obtained by Fierce Biotech, refer to a large-scale restructuring to afford late-stage drug development.

Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public

By James Waldron

Contineum Therapeutics has lowered its IPO expectations as the Johnson & Johnson-partnered biotech prepares to make the jump to the public markets this morning.

Chutes & Ladders—Lonza lands new CEO after acquiring Roche site

By Gabrielle Masson,Max Bayer

From one Swiss CDMO to another. That’s the course for Wolfgang Wienand, who plans to jump from his role as Siegfried’s CEO over to Lonza.

Fierce Biotech Layoff Tracker 2024: Sanofi 'simplifies' R&D structure, team; Amylyx lays off 70% of staff

By Gabrielle Masson,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

The unrecognized threat of PAD

By Ayla Ellison

This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.

Patient discharged with eGenesis’ genetically engineered pig kidney after successful xenotransplant procedure

By Conor Hale

In a world first, a man with end-stage renal disease is now enjoying "one of the cleanest bills of health" in a long time, following a xenotransplant procedure at Massachusetts General Hospital.

AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win

By Angus Liu

AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer.

Teladoc leadership shakeup: CEO Jason Gorevic steps down, CFO steps in

By Heather Landi

In a major corporate shift, Jason Gorevic has stepped down as CEO of virtual care giant Teladoc after leading the company for 15 years.

Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar

By Angus Liu

Eisai and Biogen's subcutaneous Leqembi faces a regulatory delay. Johnson & Johnson and Legend Biotech have expanded their contract manufacturing deal with Novartis around Carvykti. A Chinese drugmaker is seeking local approval of a biosimilar version of Novo Nordisk's Ozempic. And more.

Fierce podcasts

Don’t miss an episode

'The Top Line': The unrecognized threat of PAD

'Podnosis': A closer look at social prescribing and the impact of the arts on our health

'The Top Line': The top money raisers in biotech

Resources

Whitepaper

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

PPD®️ Laboratory Services